Search company, investor...

Founded Year



Debt - V | Alive

Total Raised


Last Raised

$38M | 1 yr ago

About Monteris Medical

Monteris Medical is a neurosurgical company that operates in the healthcare industry. The company offers a minimally invasive, robotically controlled laser thermal therapy system that uses MRI-guided laser light to destroy unwanted tissue in the brain, such as tumors and lesions. Monteris primarily serves the healthcare sector, particularly neurosurgery. It was founded in 1999 and is based in Hopkins, Minnesota.

Headquarters Location

131 Chesire Lane Suite 100

Hopkins, Minnesota, 55305,

United States




Expert Collections containing Monteris Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Monteris Medical is included in 2 Expert Collections, including Robotics.



1,974 items

This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Monteris Medical Patents

Monteris Medical has filed 34 patents.

The 3 most popular patent topics include:

  • oncology
  • radiation therapy
  • cardiac arrhythmia
patents chart

Application Date

Grant Date


Related Topics




Oncology, Cardiac arrhythmia, Radiation therapy, Medical physics, Experimental cancer drugs


Application Date


Grant Date



Related Topics

Oncology, Cardiac arrhythmia, Radiation therapy, Medical physics, Experimental cancer drugs



Latest Monteris Medical News

Monteris Medical Announces Publication of Largest Series of NeuroBlate Laser Interstitial Thermal Therapy for Biopsy-Proven Radiation Necrosis

Apr 18, 2023

News provided by Share this article Share this article with radiation necrosis as supported by evidence from 90 patients treated with NeuroBlate laser ablation MINNETONKA, Minn. , April 18, 2023 /PRNewswire/ --  Monteris Medical announced today that a new publication on laser interstitial thermal therapy (LITT) using the NeuroBlate® System to treat patients with radiation necrosis (RN) has been published in the journal, Neuro-Oncology Advances. The largest prospectively-gathered dataset, collected through the company's LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System) multi-center study and comprised of 90 patients with biopsy-proven RN, showed that LITT with NeuroBlate is a safe and highly effective minimally invasive option for the treatment of RN. The evidence also demonstrated that following the NeuroBlate procedure, patients tapered corticosteroid use rapidly, showed excellent symptom control and continued systemic cancer treatments, allowing for maximal survival benefit. The evidence gathered from this large cohort of pure RN continues to support the utilization of NeuroBlate LITT for the treatment of RN, an inflammatory process that can occur following stereotactic radiosurgery (SRS). These data showed that patients rapidly discontinued steroid use post-LITT (median time of 13 days), an important benefit, given steroid use may worsen survival rates, particularly for those on immunotherapy. Patients in the study who were undergoing chemotherapy and/or immunotherapy experienced little to no interruption in their treatments post-LITT. This is in contrast to craniotomy, which generally requires that patients pause systemic treatments to facilitate wound healing and recovery time. "LITT compares favorably to historical efficacy of craniotomy and resection yet has a degree of versatility when faced with deeper lesions or with those close to eloquent brain," said Dr. Michael D. Chan, lead author and professor of radiation oncology at Atrium Health Wake Forest Baptist in Winston-Salem, NC. "Compared to historical expectations with craniotomy, LITT has demonstrated favorable hospitalization times and favorable risk profile. It seems that LITT has truly carved itself a role in the management of post-SRS radiation necrosis alongside other tools including steroids, bevacizumab and open resection. I look forward to results of the ongoing prospective studies meant to validate the present findings." The use of stereotactic radiosurgery (SRS) has significantly expanded in recent years as brain metastases have become more common. This is due in part to advances in systemic therapy that enable the long-term control of extracranial disease. The growing use of radiotherapy has also resulted in the proliferation of post-SRS imaging changes, which may represent either RN or tumor growth, a diagnostic question best confirmed via biopsy. Laser interstitial thermal therapy with biopsy offers patients an immediate diagnostic confirmation of the disease process and is a highly effective treatment for RN with respect to local control and symptom management. "We are grateful to our investigators for their continued work to generate clinical proof that supports NeuroBlate as a surgical tool for early intervention for those patients with progressive brain metastases," said Martin J. Emerson, president and chief executive officer of Monteris. "As the leader in the LITT space, Monteris remains uniquely committed to delivering high quality evidence that physicians need when making critical patient care decisions. With more than 1,100 patients enrolled, our prospective LAANTERN study continues to demonstrate a distinct position for NeuroBlate as an evidenced-based, mainstay technology for brain tumors, radiation necrosis, and drug-resistant epilepsy." About LAANTERN LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System) is a post-market study designed to evaluate the performance and utilization of the NeuroBlate® System in the standard of care, "real-world" setting. This is the first prospective multicenter laser ablation study. All sites operate under an IRB-approved protocol and undergo rigorous data management and monitoring practices to ensure data quality and consistency. The registry will follow up to 3,000 patients for five years evaluating safety, quality of life, health economics and procedural outcomes, including survival and seizure freedom. About Monteris and the NeuroBlate System Monteris Medical is a privately held company that develops and markets innovative MR-guided ablation systems to perform minimally invasive, robotically controlled brain surgery, commonly referred to as laser ablation, LITT (Laser Interstitial Thermal Therapy) or SLA (Stereotactic Laser Ablation). The Monteris NeuroBlate System is the only minimally invasive system that enables a robotic interface for the precise and safe delivery of laser energy. The Monteris Medical NeuroBlate System is a neurosurgical tool and is intended for ablating intracranial soft tissue, including brain structures such as brain tumors, radiation necrosis, and epileptic foci (as identified by non-invasive and invasive neurodiagnostic testing, including imaging). For more information, visit . Media Contact:

Monteris Medical Frequently Asked Questions (FAQ)

  • When was Monteris Medical founded?

    Monteris Medical was founded in 1999.

  • Where is Monteris Medical's headquarters?

    Monteris Medical's headquarters is located at 131 Chesire Lane, Hopkins.

  • What is Monteris Medical's latest funding round?

    Monteris Medical's latest funding round is Debt - V.

  • How much did Monteris Medical raise?

    Monteris Medical raised a total of $207.43M.

  • Who are the investors of Monteris Medical?

    Investors of Monteris Medical include Madryn, Birchview Capital, InnovaHealth Partners, The Vertical Group, 3x5 Partners and 11 more.

  • Who are Monteris Medical's competitors?

    Competitors of Monteris Medical include Gynesonics, Endologix, IlluminOss Medical, Myomo, ViewRay and 7 more.


Compare Monteris Medical to Competitors

Endologix Logo

Endologix is a company focused on the development and manufacturing of minimally invasive treatments for aortic disorders, operating within the medical devices industry. The company's main offerings include a variety of endovascular stent grafts, which are used for the treatment of abdominal aortic aneurysms (AAA), a condition characterized by a weakening of the wall of the aorta that can lead to a balloon-like enlargement. Endologix primarily serves the healthcare sector, particularly in areas related to vascular disease and aortic disorders. It was founded in 1992 and is based in Irvine, California.

Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.


Gynesonics women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. It develops the sonata system for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The sonata system uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. Gynesonics was founded in 2005 and is based in Redwood City, California.

Arbel Medical

Arbel-medical develops minimally invasive Cryo-therapy products, for the treatment of breast tumors and other internal diseased tissue.


BioSpiral's state-of-art system aims to provide prostate cancer treatment as a minimally invasive procedure, which uses cooling & heating technologies to destroy prostate cancer.nBioSpiral was established in Sep 2006 and is operating as part of NGT Incubator. nBioSpiral prostate thermodynamics therapy is an effective, minimally invasive treatment for prostate cancer that does not involve the difficulty and complications associated with surgery, nor the harmful properties of radiation or cryotherapy .The system revolutionizes prostate cancer treatment by introducing a "one shot" treatment method under local anesthesia at the physician's clinic. BioSpiral treatment is for patients with localized prostate cancer, who look for an effective minimal invasive therapy for prostate cancer. Additionally, this treatment can also be used by patients who have local recurrence after other treatments ("salvage" treatment). Key advantages:nCost effective: short treatment, no need for O.R or hospitalizationnHighly efficient: tissue ablationnPatients: high quality of life; minimal side effects, minimal invasive, short treatment & recovery.

Pro-Duct Health

Pro-Duct Health is a medical device company focused on developing and commercializing products for non-invasive detection of breast cancer.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.